Discover These 3 Undiscovered Gems in India's Stock Market
In This Article:
Over the last 7 days, the Indian stock market has remained flat, yet it has risen 44% in the past 12 months with earnings forecasted to grow by 17% annually. In this thriving environment, identifying lesser-known stocks with strong potential can offer unique opportunities for investors.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| Kokuyo Camlin | 27.11% | 23.20% | 75.70% | ★★★★★★ |
| Le Travenues Technology | 10.32% | 26.39% | 67.32% | ★★★★★★ |
| Force Motors | 23.24% | 21.52% | 44.24% | ★★★★★☆ |
| Master Trust | 37.05% | 27.57% | 41.99% | ★★★★★☆ |
| Insolation Energy | 88.64% | 163.87% | 419.31% | ★★★★★☆ |
| Kalyani Investment | NA | 21.42% | 6.35% | ★★★★★☆ |
| Sky Gold | 127.01% | 22.02% | 48.03% | ★★★★☆☆ |
| Sanstar | 50.30% | -8.41% | 48.59% | ★★★★☆☆ |
| Innovana Thinklabs | 13.59% | 12.51% | 20.01% | ★★★★☆☆ |
Let's review some notable picks from our screened stocks.
LT Foods
Simply Wall St Value Rating: ★★★★★★
Overview: LT Foods Limited engages in the milling, processing, and marketing of branded and non-branded basmati rice and rice food products in India with a market cap of ₹117.75 billion.
Operations: Revenue from the manufacture and storage of rice stands at ₹81.21 billion.
Earnings for LT Foods grew 35.7% last year, outpacing the food industry's 13.9%. The company's net debt to equity ratio improved from 116.4% to 26.8% over five years, indicating better financial health. Trading at just below its fair value, LT Foods offers high-quality earnings and good relative value compared to peers. Recent news includes a new U.K facility with an initial £7 million investment and potential revenue of £50 million annually within two years.
-
Click here to discover the nuances of LT Foods with our detailed analytical health report.
-
Review our historical performance report to gain insights into LT Foods''s past performance.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ₹99.76 billion.
Operations: Marksans Pharma Limited generates revenue primarily from its Pharmaceuticals segment, amounting to ₹22.68 billion. The company's market cap stands at ₹99.76 billion.
Marksans Pharma, a rising player in India's pharmaceutical sector, has seen its debt to equity ratio improve from 19.9% to 11.7% over the past five years while maintaining a P/E ratio of 29.9x, which is favorable compared to the Indian market's 32.5x. Earnings grew by 21.7% last year, outpacing industry growth of 19.3%. Recent Q1 results show net income at INR 887 million and revenue at INR 6 billion, indicating robust financial health and future growth potential through M&A activities in Europe.